SOURCE: Milestone Scientific, Inc.

Milestone Scientific, Inc.

February 18, 2016 13:08 ET

Milestone Scientific Forms Global Advisory Board in Advance of the Finalization of the 400 Patient Clinical Study

Appoints Industry Veteran Bob Miglani as First Global Advisory Board Member

LIVINGSTON, NJ--(Marketwired - February 18, 2016) - Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced it has formed a Global Advisory Board to aid in the commercialization of its medical instruments and also appointed industry veteran Bob Miglani as its inaugural member.

Bob Miglani has been with Pfizer Inc. for 23 years, where he held various senior sales, pricing, reimbursement, corporate affairs, as well as market access roles, and was responsible for managing projects and strategies in multiple countries including the U.S., Europe and India. His most recent role has been as Senior Director, External Medical Affairs at Pfizer Inc., where he has been developing innovative partnerships with medical and healthcare organizations in the U.S and around the world in the area of health and wellness innovation, new customer partnerships and public health. In 2014, he was awarded the Top 50 Asian Americans in Business Award.

Leonard Osser, CEO of Milestone Scientific commented: "The establishment of our Global Advisory Board will be an important resource as we move toward the worldwide rollout of our epidural instrument. We are delighted to welcome Bob as the first member of our new Global Advisory Board. He brings extensive business-to-business and consumer experience to help us realize the full potential of our instruments. The appointment comes at a key inflection point as we are now entering the final stage of U.S. clinical trials of our epidural instrument and we are close to reaching our enrollment goal of up to 400 patients. Based on the interim analysis of the clinical study that achieved the goal set by the FDA IDE Investigational Plan, we expect the final clinical trial data and accompanying statistical analysis to be completed in the next few weeks. We anticipate that the additional validation from U.S clinical trials and FDA approval will also accelerate the commercial launch of our epidural instrument in Europe and around the world."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • Contact:
    David Waldman or Natalya Rudman
    Crescendo Communications, LLC
    Email: mlss@crescendo-ir.com
    Tel: 212-671-1020